Unknown

Dataset Information

Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer.


ABSTRACT:

Purpose

The aim of this study was to assess the effectiveness and tolerability of atezolizumab plus carboplatin and etoposide combination chemotherapy in elderly patients with extensive-disease (ED) small-cell lung cancer (SCLC).

Methods

This retrospective study evaluated 65 SCLC patients who received atezolizumab, carboplatin, and etoposide for ED-SCLC in nine study institutions between August 2019 and September 2020. Clinical efficacy, assessed according to response rate and survival, and toxicity were compared between the elderly (n = 36 patients; median age: 74 years [range: 70-89 years]) and the non-elderly group (n = 29 patients; median age: 67 years [range: 43-69 years]).

Results

The response rate was 73.8% (80.5% in the elderly group and 65.5% in the non-elder

SUBMITTER: Shiono A 

PROVIDER: S-EPMC9844637 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature